Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PROK 
ProKidney Corp. (PROK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PROK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.83
1 Year Target Price $5.83
| 4 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.17% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.81B USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 7 | Beta 1.79 | 52 Weeks Range 0.46 - 5.95 | Updated Date 09/14/2025 |
52 Weeks Range 0.46 - 5.95 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -17967.87% |
Management Effectiveness
Return on Assets (TTM) -25.3% | Return on Equity (TTM) -40.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 44473954 | Price to Sales(TTM) 3438 |
Enterprise Value 44473954 | Price to Sales(TTM) 3438 | ||
Enterprise Value to Revenue 84.39 | Enterprise Value to EBITDA 2.13 | Shares Outstanding 134994000 | Shares Floating 86722544 |
Shares Outstanding 134994000 | Shares Floating 86722544 | ||
Percent Insiders 28.84 | Percent Institutions 30.46 |
Upturn AI SWOT
ProKidney Corp.
Company Overview
History and Background
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease (CKD). The company was founded in 2015.
Core Business Areas
- Renal Cell Therapy Development: Developing REACT, a proprietary cell therapy to treat CKD.
Leadership and Structure
Details about leadership team and organizational structure are publicly available on ProKidney's investor relations website. Information includes CEO, CFO, and board members.
Top Products and Market Share
Key Offerings
- REACT: REACT is a cell therapy in clinical trials for the treatment of chronic kidney disease (CKD). Market share is currently 0% as it's not yet approved. Competitors include companies developing other novel therapies for CKD, such as Travere Therapeutics, Calliditas Therapeutics and pharmaceutical companies with established drugs for managing symptoms of CKD such as Amgen and AstraZeneca.
Market Dynamics
Industry Overview
The kidney disease treatment market is large and growing, driven by an aging population and increasing prevalence of diabetes and hypertension.
Positioning
ProKidney is positioned as a pioneer in cell therapy for kidney disease. Their competitive advantage lies in their proprietary REACT technology.
Total Addressable Market (TAM)
The global chronic kidney disease market is estimated to be worth over $90 billion. ProKidney is aiming to capture a significant portion of this market with its REACT therapy, but it depends on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary REACT technology
- Focus on a large unmet need
- Strong management team
- Cell therapy platform
Weaknesses
- Clinical trial risk
- Regulatory risk
- Manufacturing complexity
- Limited operating history
Opportunities
- Positive clinical trial results
- Regulatory approval
- Partnerships with pharmaceutical companies
- Expansion to other kidney diseases
Threats
- Competition from established therapies
- Failure of clinical trials
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- TRAV
- CLLS
- AMGN
- AZN
Competitive Landscape
ProKidney is pursuing a novel approach with cell therapy, which could differentiate it from existing treatments. It faces competition from established pharmaceutical companies with approved drugs and other biotech companies developing new therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by advancing REACT through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of REACT.
Recent Initiatives: Focus on advancing Phase 3 clinical trials for REACT.
Summary
ProKidney is an early-stage biotech company with a high-risk, high-reward profile. The company's success hinges on positive clinical trial results for its REACT therapy. While it faces competition and regulatory hurdles, it also has the potential to disrupt the kidney disease treatment market. ProKidney is still in early stages of development with no revenue at this time.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ProKidney Corp. investor relations website
- SEC filings
- Market research reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data. The rating is based on limited public information and is a conceptual illustration.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProKidney Corp.
Exchange NASDAQ | Headquaters Winston-Salem, NC, United States | ||
IPO Launch date 2022-07-12 | CEO & Director Dr. Bruce Culleton M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 204 | Website https://prokidney.com |
Full time employees 204 | Website https://prokidney.com | ||
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.